Neurologie [Neurology].

Détails

ID Serval
serval:BIB_2E4541BC9980
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Neurologie [Neurology].
Périodique
Revue Médicale Suisse
Auteur(s)
Chabwine J.N., Rossetti A.R., Hirt L., Kuntzer T., Schluep M., Michel P., Démonet J.F., du Pasquier R.A., Vingerhoets F.G.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
8
Numéro
323
Pages
46-50
Langue
français
Notes
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish
Résumé
In 2011, new oral anticoagulants for atrial fibrillation are available and the ABCD3-I score predicting stroke after TIA updates the ABCD2 score. New McDonald criteria allow faster MS diagnosis and the first oral treatment (fingolimod) for MS can be prescribed. A new anti-antiepileptic drug (retigabine) is available and sodium valproate has long term neurological adverse effects after in utero exposure. Among Parkinson disease treatments, deep brain stimulation is extending applications and dopamine agonists with extended release are as efficient and well tolerated as standard forms at long term scale. Monoclonal antibodies and immunosuppressant agents are proposed as good alternatives in the treatment of chronic dysimmune polyneuropathies. Gene therapy for the treatment of genetic myopathies is progressing.
Mots-clé
Antibodies, Monoclonal/therapeutic use, Anticonvulsants/therapeutic use, Atrial Fibrillation/diagnosis, Atrial Fibrillation/drug therapy, Carbamates/therapeutic use, Chronic Disease, Deep Brain Stimulation, Dopamine Agonists/therapeutic use, Epilepsy/diagnosis, Epilepsy/drug therapy, Gene Therapy/methods, Humans, Immunosuppressive Agents/therapeutic use, Ischemic Attack, Transient/diagnosis, Ischemic Attack, Transient/drug therapy, Multiple Sclerosis/diagnosis, Multiple Sclerosis/drug therapy, Muscular Diseases/diagnosis, Muscular Diseases/genetics, Neurology/trends, Parkinson Disease/diagnosis, Parkinson Disease/drug therapy, Phenylenediamines/therapeutic use, Polyneuropathies/diagnosis, Polyneuropathies/drug therapy, Propylene Glycols/therapeutic use, Sphingosine/analogs & derivatives, Sphingosine/therapeutic use, Stroke/drug therapy, Treatment Outcome, Valproic Acid/therapeutic use
Pubmed
Création de la notice
06/06/2012 19:19
Dernière modification de la notice
20/08/2019 14:12
Données d'usage